Executives from Merck & Co. (NYSE:MRK) and Seagen (Nasdaq:SGEN) are reportedly considering a $40 billion acquisition deal. Readington, New Jersey–based Merck has offered to spend about $200 per share for Seagen, according to The Wall Street Journal. Executives from the company aim to finalize the deal before Merck announces its Q2 earnings on July 28, according…
Merck reportedly mulling Seagen acquisition
Approximately one month after Seagen (Nasdaq:SGEN) CEO Clay Siegall resigned following a domestic abuse arrest, Merck & Co. (NYSE:MRK) is considering purchasing the company, according to WSJ. One potential hurdle is the possibility of increased antitrust enforcement from the DOJ and FTC focused on the pharmaceutical sector. To sidestep such risks, the two companies could enter a…
Seagen CEO Siegall resigns after domestic abuse arrest
Seagen (Nasdaq:SGEN) has announced that its CEO Clay Siegall has resigned following a domestic abuse arrest in April. Police charged Siegall with fourth-degree misdemeanor assault. He maintains his innocence. The company has named its lead independent director Felix Baker to assume the role of chair of the board of directors. Seagen Chief Medical Officer Dr.…